MARKET NEWS

Qualigen Therapeutics Secures Option to Negotiate License for G-Quadruplex Anti-Cancer Technology 
Enzo Announces its Molecular Test Detects Current COVID-19 Variants
VYNE Therapeutics Announces Development Program for  Combination Topical Gel 
Silo Pharma Enters Exclusive Option Agreement With the University of Maryland
NGM Bio Initiates Expansion of Ongoing Phase 1b Proof-of-Concept Study
Aptamer Group Extends Collaboration With AstraZeneca to Explore Next-Generation Drug Delivery Approaches

  FEATURED EDITORIAL

  COMPANY PROFILE

Singota Solutions is a contract development and manufacturing organization (CDMO) focused on getting products to patients faster by being agile, accountable, and transparent. Founded in 2006, and headquartered in Bloomington, Indiana, Singota provides responsive, quality driven outsourcing services. Singota can fill parenterals into ready-to-use vials, syringes, or cartridges utilizing our gloveless, robotic, aseptic filling workcell for pre-clinical, clinical, and small commercial therapies. Our manufacturing process ensures freedom from in-process human intervention by not only removing the impact of operators from the initial aseptic environment but also by removing operator variability from the filling process. Click here for more.

  EXCLUSIVE ONLINE CONTENT

Ridgeback Biotherapeutics & Merck Announce Preliminary Findings From Phase 2a Trial of Investigational COVID-19 Therapeutic Molnupiravir

Ridgeback Biotherapeutics & Merck Announce Preliminary Findings From Phase 2a Trial of Investigational COVID-19 Therapeutic Molnupiravir

Merck and Ridgeback Biotherapeutics recently announced preliminary results from Ridgeback’s Phase 2a randomized, double-blind, placebo-controlled trial to evaluate the safety, tolerability, and efficacy to eliminate SARS-CoV-2 viral RNA….

Veru Receives FDA Agreement to Advance VERU-111 Into Phase 3 Study 

Veru Receives FDA Agreement to Advance VERU-111 Into Phase 3 Study 

Veru Inc. recently announced the FDA agreed in an End of Phase 2 meeting, to advance VERU-111 into a Phase 3 registration clinical study based on the clinically meaningful benefits observed with….

Schreiner MediPharm & AARDEX Offer Smart Digital Therapy Management Solution for Clinical Trials

Schreiner MediPharm & AARDEX Offer Smart Digital Therapy Management Solution for Clinical Trials

Schreiner MediPharm, a Germany-based global provider of innovative functional label solutions for the healthcare industry, has collaborated with AARDEX Group, an expert in digital….

LEXEO Therapeutics Announces License Agreement & Consolidation of Comprehensive Preclinical Data Package

LEXEO Therapeutics Announces License Agreement & Consolidation of Comprehensive Preclinical Data Package

LEXEO Therapeutics recently announced it has licensed worldwide intellectual property rights and preclinical data from Adverum Biotechnologies to its….

WuXi AppTec Completes Acquisition of OXGENE to Further Strengthen Cell & Gene Therapy Service Offerings for Global Customers

WuXi AppTec Completes Acquisition of OXGENE to Further Strengthen Cell & Gene Therapy Service Offerings for Global Customers

WuXi AppTec recently announced that it has completed the acquisition of OXGENE, a pioneering UK-based contract research and development organization that designs and develops scalable gene….

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

March 17 – Analytical Instruments
March 24 – Parenteral Contract Manufacturing